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The aim of this study was to assess the most frequent multidrug resistant (MDR) profiles of the main bacteria implicated in
community-acquired urinary tract infections (UTI). Only the MDR profiles observed in, at least, 5% of the MDR isolates were
considered. A quarter of the bacteria wereMDR and themost commonMDRprofile, including resistance to penicillins, quinolones,
and sulfonamides (antibiotics with different mechanisms of action, all mainly recommended by the European Association of
Urology for empirical therapy of uncomplicated UTI), was observed, alone or in association with resistance to other antimicrobial
classes, in themain bacteria implicated inUTI.The penicillin class was included in all the frequentMDRprofiles observed in the ten
main bacteria and was the antibiotic with the highest prescription during the study period.The sulfonamides class, included in five
of the six more frequent MDR profiles, was avoided between 2000 and 2009.The results suggest that the highMDR percentage and
the high diversity of MDR profiles result from a high prescription of antibiotics but also from antibiotic-resistant genes transmitted
with other resistance determinants on mobile genetic elements and that the UTI standard treatment guidelines must be adjusted
for the community of Aveiro District.
1. Introduction
Multidrug resistant (MDR) bacteria are more usually associ-
ated with nosocomial infections. However, their emergence
at the community level has increased, making the infections
treatment more difficult, namely, the most common ones,
such as the urinary tract infection (UTI). Uncomplicated
cystitis (infection of bladder) in women is the most common
UTI and according to the European Association of Urology
(2013) is defined as the growth of a single pathogen of >103
colony-forming units mL−1 from properly collected mid-
stream urine [1]. Some studies performed at community level
showed that MDR bacterial percentage observed among the
most prevalent bacteria involved in the community-acquired
UTI, Escherichia coli, varied between 38 and 54% [2, 3].
The increasing spread of bacterial resistance to antimi-
crobials at the community setting is promoted by sev-
eral factors. The overuse and misuse of antimicrobials in
human medicine, in veterinary and in agriculture represent
some of the behaviours responsible for selective pressure
which enables the selection and spread of clones that carry
antibiotic-resistance genes [4]. Measures to prevent and
control the increase of antimicrobial resistance as well as the
dissemination of resistance genes are crucial. One of these
measures is the reduction of antibiotic consumption by the
implementation of norms for its rational use.
Resistance to antibiotics occurs classically as a result of
drug modification, target alteration, and reduced accumula-
tion owing to decreased permeability and/or increased efflux.
It may be an innate feature of a microorganism or may result
from mutation or acquisition of exogenous resistance genes
[5].The acquisition of resistant genes has been well described
in the literature [6, 7] and it is particularly important because
acquisition regularly might confer cross- or coresistance [7–
9] which may turn bacteria MDR to specific antibiotics even
when these antibiotics are not frequently prescribed or had
even been abolished.
The 2013 guidelines of the European Association of
Urology (EAU) recommend for empirical treatment of acute
uncomplicated cystitis TMP-SMX (if the local resistance
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is less than 20% for E. coli), nitrofurantoin, fosfomycin
trometamol and pivmecillinam (as first-line therapy). Fluoro-
quinolones may be used only as alternative therapy and their
use must be avoided to treat uncomplicated cystitis whenever
possible [1]. According to the 2009 EAU guidelines, however,
fluoroquinolones were recommended as first-line empirical
therapy [1, 10].
This study aimed to identify the most frequent multidrug
resistance profiles of the main ten bacteria implicated in UTI
acquired at the community in Aveiro District (Portugal).
The results of our previous study [11] showed that (1) from
the main ten bacteria implicated in UTI (Escherichia coli,
Staphylococcus aureus, Proteus mirabilis, Klebsiella spp., Ente-
rococcus faecalis, Proteus vulgaris, Pseudomonas aeruginosa,
Enterobacter spp., Staphylococcus epidermidis, and Providen-
cia spp.), E. coli was implicated in more than 50% of the UTI;
(2) the UTI was more frequent in women (78.5%) and its
incidence increased with age; (3) the resistance to antibiotics
of the bacteria most implicated in UTI, E. coli, was lower
than those of the other pathogens implicated in UTI; and
(4) the bacteria isolated from males were less resistant than
those isolated from females and this difference increased
with the patient age. The identification of the MDR profiles
in these bacteria most implicated in UTI is essential for
health professionals to improve and establish an appropriate
empirical therapy.
2. Methods
2.1. Study Period and Urine Sampling. In this retrospective
study, all urine samples from patients of Aveiro District pre-
senting clinical symptoms of urinary tract infection treated
in ambulatory regime, collected at the Clinical Analysis
Laboratory Avelab (Aveiro, Portugal) during the period
2000–2009, were included as described by Linhares et al.
[11]. For each patient the age, sex, urine culture results,
identification of the bacterial strain responsible for UTI, and
the correspondent Antimicrobial Susceptibility Test (AST)
results were registered.The Ethical Committee of the Clinical
Analysis Laboratory Avelab approved this study.
The midstream clean-catch technique was used to collect
the early urine sample but, for children up to two years, the
urine sample was collected using a collection bag as described
by Linhares et al. [11].The urine samples were analyzedwithin
one hour after collection. When this procedure was not
possible the urine samples were stored at 4∘C and processed
until 24 h after collection.
2.2. Microscopic Examination. The urine samples were
homogenized and concentrated by centrifugation and the
pellet was directly examined or stained by the Gram tech-
nique as described by Linhares et al. [11].
2.3. Urine Culture. Theurine samples were inoculated in agar
plates using the streak plate method. Specific and differential
culture media were used to isolate and identify the bacteria
[11]. The samples were classified according to Linhares et
al. [11] as contaminated when polymorphic bacterial growth
was observed (exclusion criterion); as negativewhen bacterial
growth was lower than 103 cfumL−1 (exclusion criterion);
and as positive (inclusion criterion) when monomorphic
bacterial growthwas higher than 105 cfumL−1. For these cases
and for urine cultures with monomorphic bacterial growth
between 104 and 105 cfumL−1 the AST was performed.
2.4. Identification of Bacterial Isolates. The bacterial strains
studied in this work were isolated and identified previously
as described by Linhares et al. [11]. Biochemical tests were
selected based on the morphology of the isolated bacteria
and on the results of the microscopic examination of the
Gram-stained smear. Briefly, the Enterobacteriaceae were
differentiated using the Kligler (BD BBL, 211317), Tryptone
(BD BBL, 264410), Simmons Citrate (BD BBL, 211620),
and Urea (Oxoid, CM0053) media. To differentiate between
species of the same genus some biochemical tests were done
[11].
2.5. Antimicrobial Susceptibility Test. The modified Kirby-
Bauer disk diffusion method was used to perform the
AST [11]. Briefly, a bacterial suspension in physiological
saline solution was spread platted on Mueller-Hinton Agar.
Antimicrobial-impregnated disks (BD BBL, Sensi-Disc) were
placed on the cultures medium surface. For the Enterobacte-
riaceae, the antibiotics amoxicillin, cephradine, cefuroxime,
amoxicillin-clavulanic acid (AMC), amikacin, gentamicin,
ciprofloxacin, trimethoprim-sulfamethoxazole (SXT), and
nitrofurantoin were tested. For Enterococcus spp. and Strepto-
coccus spp., penicillin, imipenem, amoxicillin-clavulanic acid,
gentamicin, ciprofloxacin, nitrofurantoin, and vancomycin
were used. For Staphylococcus spp., penicillin, cephradine,
amoxicillin-clavulanic acid, gentamicin, ciprofloxacin, nitro-
furantoin, and vancomycin were used. For Pseudomonas
spp., piperacillin, cefepime, aztreonam, imipenem, amikacin,
gentamicin, and ciprofloxacin were tested. After plates incu-
bation, at 37∘C for 18–24 hours, the antibiotic efficacy was
determined by measuring the diameter of the zones of
inhibition [12]. Bacterial strains were classified as susceptible
(S), intermediate (I), or resistant (R) according the diameter
of the inhibition zone [12].
2.6. Statistical Analysis. The Statistical Package for the Social
Sciences (SPSS) 16.0 for Windows was used to analyze data.
A 𝜌 value of ≤ 0.05 was considered significant.The normality
of data, homogeneity, and independence of variance were
checked before analysis. As most of the variables failed these
statistical method assumptions, the nonparametric Mann-
Whitney U and Kruskal-Wallis tests were used. To analyze
the bacterial multidrug resistance (MDR) patterns of the
main ten bacteria implicated in UTI, only the antibiotics that
were used in more than 85% of the cases were included.
The uropathogens resistant to three or more antimicrobial
classes were considered MDR [13]. To simplify the statistical
treatment, only the MDR profiles observed, at least, in 5% of
the MDR bacteria were selected.
3. Results
3.1. Multidrug Resistance of the Main Bacteria. The main ten
bacteria were implicated in 17580 UTI, 4376 (25%) being
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Figure 1: Incidence of MDR isolates of the main bacteria implicated in UTI by sex. The incidence of MDR isolates of the main ten bacteria
implicated in UTI, during the study period, was determined by female and male patients.
multidrug resistant. A higher incidence of UTI caused by
MDR bacteria was observed among male patients (35.4%)
than among female patients (22.1%). The incidence of E. coli
and P. vulgaris MDR isolates was higher in male patients
during all the study period and the incidence ofMDR isolates
of Klebsiella spp., P. aeruginosa, P. mirabilis, Enterobacter spp.,
S. aureus, and E. faecalis was higher in male patients in half
of the study period (Figure 1).
A higher percentage of MDR isolates was also observed
among elderly patients (30.2%).
3.2. Prevalence of MDR Profiles. The most common MDR
profile (among those presenting an incidence higher than
5%) includes resistance to penicillins, quinolones, and sulfon-
amides (PQS) and was found in five of the main ten bacteria
implicated in UTI (responsible for 80.2% of all UTI), namely,
in E. coli (21.7%), S. aureus (15.2%), Klebsiella spp. (6.8%),
E. faecalis (12%), and S. epidermidis (28.2%) (Figure 2). For
the other bacteria, with exception of P. aeruginosa (for which
sulphonamides are not used), this MDR profile was also
observed but associated with resistance to other antibiotic
classes.
The three types of MDR profiles presented in E. coli
isolates (resistance (1) to “PQS”; (2) to cephalosporins, peni-
cillins, and sulfonamides (CPS); and (3) to cephalosporins,
penicillins, quinolones, and sulfonamides (CPQS)) were
also found in S. aureus, S. epidermidis, and Providencia
spp. (Figure 2). The bacterium Enterobacter spp., with eight
MDR profiles (all including resistance to penicillins and
cephalosporins), showed the higher diversity when compared
with other Enterobacteriaceae such as E. coli that showed the
lowest diversity, three MDR profiles.
The six MDR profiles most frequent in the ten main
bacteria isolated from UTI patients were observed in 43.4%
of MDR bacteria and all included resistance to the penicillins
class. The quinolones were the less frequent in these MDR
profiles being, however, present in 50% of the 6MDR profiles
(Table 1).
The most common MDR profile observed for the main
bacteria implicated in UTI, which includes resistance to
Table 1: Percentage of the most common MDR profiles (incidence
higher than 5% in MDR bacteria).
MDR profiles Number ofMDR isolates
% MDR
isolates
Penicillins, quinolones, and
sulfonamides 551 12.6
Cephalosporins, nitrofurans, and
penicillins 341 7.8
Cephalosporins, penicillins, and
sulfonamides 290 6.6
Cephalosporins, penicillins,
quinolones, and sulfonamides 262 6.0
Cephalosporins, nitrofurans,
penicillins, quinolones, and
sulfonamides
234 5.3
Cephalosporins, nitrofurans,
penicillins, and sulfonamides 223 5.1
“PQS,” was the same observed for the bacteria isolated from
male and female patients (Figure 3), but the incidence of
this MDR profile was higher in bacteria isolated from female
patients (12.9%) than from male (11.9%) ones. The second
MDR profile (8.3%) more frequent in bacteria isolated from
male patients includes resistance to five different antimi-
crobial classes, namely, resistance to cephalosporins, nitro-
furans, penicillins, quinolones, and sulfonamides (CNPQS)
(Figure 3), whereas the second MDR profile (8.5%) among
bacteria isolated from female patients showed resistance to
three different antimicrobial classes (cephalosporins, nitro-
furans, and penicillins (CNP)).
The MDR profile more common (which includes resis-
tance to “PQS”) in the main bacteria implicated in UTI
was the same for bacteria isolated from adolescents, young
adults, adults, and elderly patients and its incidence increased
with the age of the patients. Contrarily, in bacteria isolated
from children, this MDR profile was the third most frequent
profile (7.8%), and for this group the most frequent MDR
profile included resistance to “CPS” (14.1%) (Figure 4). A high
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Figure 2: Variation of the MDR profiles in the main bacteria implicated in UTI during the study period. Only the MDR profiles in which
incidence was higher than 5% in the MDR bacteria were included. P: penicillins; Q: quinolones; S: sulfonamides; Ce: cephalosporins; N:
nitrofurans; A: aminoglycosides; M: monobactams.
diversity of different MDR profiles was observed for bacteria
isolated from adolescents (8 profiles). The lowest number of
MDR profiles was observed for bacteria isolated from young
adults for whom only 4 differentMDR profiles were observed
(Figure 4).
The incidence of 3 most frequent MDR profiles (resis-
tance to (1) “CPS”; (2) “CNP”; and (3) cephalosporins,
nitrofurans, penicillins, and sulfonamides (CNPS))was stable
during the study period (Figure 5); however, the incidence
of the other 3 most frequent MDR profiles changed over the
study period, namely, those that confer resistance to “CPQS”
(increase of 12.6%); to “CNPQS” (increase of 6.4%); and to
“PQS” (increase of 2.7%) (Figure 5).
4. Discussion
Multidrug resistance was observed among the most preva-
lent bacteria involved in the community-acquired UTI, a
quarter of these bacteria being resistant to three or more
antimicrobials of distinct classes, and themost incidentMDR
profile includes resistance to “PQS.”
The most common MDR profile (resistance to “PQS”)
was found in five of the main ten bacteria implicated in
UTI (E. coli, S. aureus, Klebsiella spp., E. faecalis, and S.
epidermidis) but was also observed in the other five bacteria
implicated in UTI which present simultaneously resistance
to other antibiotic classes. As sulfonamides are not used for
P. aeruginosa this MDR profile was not observed for this
bacterium.This MDR profile includes most of the antibiotics
recommended by the European Association of Urology for
empirical therapy of uncomplicated UTI which suggest that
the UTI standard empirical therapy treatment guidelines
must be adjusted to the community of Aveiro District.
Moreover, this MDR profile includes antibiotics with three
different mechanisms of action which limits the therapeutic
options available to treat UTI.
Few similar studies, performed at community level, are
available for the main implicated bacteria in UTI, which
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Figure 3: Incidence of the most frequent MDR profiles by sex. Only the MDR profiles in which incidence was higher than 5% in the MDR
bacteria were included. P: penicillins; Q: quinolones; S: sulfonamides; Ce: cephalosporins; N: nitrofurans.
makes comparison difficult of the prevalence of the MDR
profiles observed in this community with those found in
other locations. However, for the most implicated bacterium
in UTI, E. coli, similar studies showed that ciprofloxacin-
resistant E. coli isolates were simultaneously resistant to
ampicillin and to SXT [14]. Another study also showed that
fluoroquinolone-resistant strains of E. coli were resistant to
AMC and to SXT [15].
Thepresence of penicillins, quinolones, and sulfonamides
in the most common MDR profile would be associated with
the high prescription of these antimicrobials classes in Aveiro
community between 2000 and 2009. This relationship was
observed for two of these antimicrobial classes, penicillins
and quinolones, but not for the sulfonamides.
The penicillins class was included in the most frequent
MDR profile and also in the other 5 MDR profiles more
frequently among the ten main bacteria. The high adminis-
tration of penicillins in Portugal at community level between
2000 and 2009 [16, 17] and the ESBL-production among
the main bacteria involved in UTI [18] may explain the low
efficacy of penicillins in the treatment of these infections.
The quinolones, although included in the most common
MDR profile, were the antimicrobial class less frequent in the
6 MDR profiles observed in the main ten bacteria implicated
inUTI butwere yet present in 50%of the 6MDRprofiles. Por-
tugal continues to be the third country among the European
countries with the highest quinolones consumption which
may explain the presence of this antimicrobial class in the
most common MDR profile [16, 17].
The sulfonamides were observed in 83% of the main
MDR profiles among the bacteria more implicated in UTI.
However, contrarily to penicillins and quinolones, the sul-
fonamides were the antimicrobial less prescribed between
2000 and 2009 in Portugal [16], meaning that their presence
in the most frequent MDR profiles is not associated with
their prescription. Some studies showed that the decrease
of antibiotics consumption among outpatients was followed
by a significant decrease of resistance to these antibiotics
[19, 20]. However, a recent finding in UK contradicted these
studies because despite the prescription of sulfonamides
being drastically reduced and even almost abolished the resis-
tance to these antimicrobials by E. coli remained high [21].
These results, as well as those obtained in the present study,
may be explained by the often close link of sulfonamide-
resistant gene with other resistance determinants on mobile
genetic elements such as plasmids that also include genes
encoding resistance to other antibiotics, which continued to
be administered, allowing the selection of these multiresis-
tance plasmids and consequently maintaining sulfonamide
resistance [21, 22]. Another possible explanation is the fitness
cost that determines the rate at which a decrease of resistance
will occur in response to the reduction of antimicrobials use
[23]. According to Lipsitch [23] the bacteria do not pay a high
fitness cost on the transmissibility of sulfonamide resistance
and even when antimicrobials pressure is removed, resistant
strains remain [22]. The sul2 is the most prevalent gene and
its acquisition represents the most common mechanism that
enables bacteria to maintain sulfonamide resistance over the
time.
The close link of antibiotics-resistant gene, with other
resistance determinants on mobile genetic elements and
probably the low fitness cost to maintain antimicrobial resis-
tance, can also explain the highest diversity of MDR profiles
observed for Enterobacter isolates. Zervos et al. [24] observed
in Enterobacter sp. isolates the presence of three integron-
mediated resistance sets that can be maintained without
biological cost, allowing, by this way, the maintenance of
resistant bacterial strains even when the antibiotic selective
pressure is reduced [25].
The presence of quinolones in 50% of the most common
MDR profiles and the high resistance among the main
bacteria implicated in community-acquired UTI may be
explained by the high consumption levels. Studies performed
at community level [24] showed that a huge decrease of
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Figure 4: Incidence of the most frequent MDR profiles by age groups. Only the MDR profiles in which incidence was higher than 5% in
the MDR bacteria were included. P: penicillins; Q: quinolones; S: sulfonamides; Ce: cephalosporins; N: nitrofurans; A: aminoglycosides; M:
monobactams.
quinolones prescription may contribute to diminishing the
prevalence of resistance to this antimicrobial class since
bacteria pay a high fitness cost on the transmissibility of
quinolone resistance [22].
Although only a slight increase (about 2.7%) in the inci-
dence of the six most common MDR profiles was observed
during the study period, the MDR profiles that include
simultaneously resistance to quinolones and cephalosporins
(corresponding to the fourth and fifth more frequent MDR
profiles) showed a higher increase (about 12.6 and 6.4%,
resp.). The increase of resistance to cephalosporins may be
related with a possible increase of ESBL-production among
Enterobacteriaceae that also confers resistance to other beta-
lactams antibiotics, including third- and fourth-generation
cephalosporins [26]. In addition to ESBLs, other less frequent
enzymes, also clinically important as plasmid-mediated
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Figure 5: Incidence of the six most frequent MDR profiles during the study period. Only the MDR profiles in which incidence was higher
than 5% in the MDR bacteria were included.
AmpC (first described for E. coli), confer resistance tomost of
the penicillins, to beta-lactamase inhibitor plus beta-lactam
combinations, and to first- (cefazolin and cefalotin) and
second-generation cephalosporins (cefoxitin) [27]. Accord-
ing to the literature, quinolone resistance is associated with
ESBL-production, being the production of CTX-M, enzymes
common among bacteria implicated in community-acquired
UTI, namely, Enterobacteriaceae such as E. coli, a serious
cause of community-acquired UTI worldwide [28]. Sev-
eral studies showed that genes conferring plasmid-mediated
quinolone resistance have been associated with blaCTX-
M genes that typically enable hydrolyze of third-generation
cephalosporins, such as cefotaxime, more efficiently than to
ceftazidime [29]. High frequency of quinolone resistance was
found in ESBL-producing E. coli (70%) [30]. This association
can explain the increase in the incidence of MDR profiles
including these two antimicrobials along the study period.
The incidence of the most common MDR profile was
higher in MDR bacteria isolated from female patients and
its incidence increased with the age of the patients. Most
of the UTI in men are complicated, being associated with
structural or functional abnormality in urinary tract, requir-
ing frequently prolonged antimicrobial therapy, and needing
antimicrobials that can reach high therapeutic concentrations
in the prostatic tissues, namely, drugs that are able to cross
the electrically charged lipid membrane of the prostate
epithelium [31]. Probably for these reasons, male patients are
more likely to develop resistance to antibiotics. The increase
of the incidence of the most common MDR profile with
the age of the patients may be explained by the increase of
the number and duration of hospital admissions and due
to the immune system fragility of the elderly patients. The
incidence of themost commonMDRprofile was higher when
bacteria were isolated from young adults, adults, and elderly
patients; however, the same was not observed for MDR
bacteria isolated from children. The absence of quinolones
in the most frequent MDR profile (including resistance to
cephalosporins, penicillins, and sulfonamides) observed for
bacteria isolated from children may be explained by the
restriction of these antimicrobials in paediatric patients due
to the potential of adverse cartilaginous effects [32]. Never-
theless, the quinolones prescription for paediatric patients
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has increased during the last years, their use being recom-
mended by the American Academy of Pediatrics in specific
clinical settings, including urinary tract infections caused by
Gram-negative bacteria, P. aeruginosa, or other multidrug
resistant bacteria [32]. Despite these evidences, the MDR
profile, including “PQS,” was the third MDR profile more
observed amongMDRbacteria isolated from children, which
according to Charalabopoulos et al. [31] may be due to
person-to-person transmission between families, in day care
or school settings, and even the use of fluoroquinolones in
poultry populations [29].
5. Conclusion
As (1) the most common MDR profile observed in the main
ten bacteria includes antibiotics with three different mecha-
nisms of action; (2) the most common MDR profile includes
themain antibiotics recommended by the European Associa-
tion of Urology for empirical therapy of uncomplicated UTI;
(3) two of the three antibiotics (penicillin and quinolones)
included in the most incident MDR profile and also present
inmore than 50% of the sixmore frequentMDRprofiles were
regularly prescribed during the study period; and (4) five of
the six more frequent MDR profiles, comprising the most
common MDR profile, include resistance to an antibiotic
(sulfonamides) that during the study period was avoided and
lately even abolished, the results of this study suggest that
(1) the high percentage of MDR bacteria (25%) and the high
diversity ofMDR profiles (6 profiles with an incidence higher
than 5%) result from a high prescription of antibiotics but
also from antibiotic-resistant genes that are transmitted with
other resistance determinants on mobile genetic elements
and (2) the UTI standard treatment guidelines must be
adjusted for the community of Aveiro District.
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